Summary

Overview
Global Pediatric Oncology Drugs Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031
Paediatric oncology is the branch of medicine dedicated to diagnosing and treating cancer in children. Childhood cancer, though rare compared to adult cancer, presents unique challenges due to the developmental stage of young patients and the distinct nature of paediatric tumours.
Market Dynamics: Drivers & Restraints
Rise of innovations in pediatric oncology
Advancements in medical research, such as genomics, immunotherapy, and targeted therapies, are revolutionizing pediatric oncology, resulting in more effective and less toxic treatments for children with cancer.
Precision oncology is one of the advancements in pediatric oncology where the goal of precision oncology is to identify drugs predicted to work against tumours with specific mutations, etc. As noted above, The MATCH trial has demonstrated the feasibility of identifying personalised therapeutic options for pediatric patients with difficult-to-treat cancer.
Examples of recent precision oncology success stories in pediatric oncology include the utilization of NTRK inhibitors for rare NTRK pediatric solid tumours, such as infantile fibrosarcoma and RAF/MEK inhibitors for the treatment of low-grade gliomas in children.

Lack of professionals
Primary care infrastructure needs improvement, and primary care providers should be educated to recognize pediatric malignancies and provide appropriate referrals. Formal research training for physicians in newly developed pediatric oncology units is also lacking. Fellowship training programs should consider additional clinical and research experiences to expand expertise in designing and conducting research to improve patient outcomes.

For more details on this report ? Request for Sample
Segment Analysis
The global pediatric oncology drugs market is segmented based on drug type, indication, route of administration end-user and region.
The Eflornithine [Iwilfin] from the drug type segment accounted for approximately 32.3% of the pediatric oncology drugs market share
The Eflornithine [Iwilfin] from the drug type segment accounted for approximately 32.3%. Eflornithine is a type of targeted therapy called a kinase inhibitor. A kinase is an enzyme that promotes cell growth. There are many types of kinases, which control different phases of cell growth.
For instance, in December 2023, the Food and Drug Administration approved eflornithine (IWILFIN, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like drug launches, FDA approvals, prevalence of pediatric neuroblastoma and the region's advanced medical facilities. This is due to positive government initiatives and an increase in research collaboration. The U.S. holds the highest share in this area because of its patient population, supportive legislation, and advanced healthcare market.
For instance, in March 2024, Caris Life Sciences, a leading AI TechBio company, announced a collaboration with the Beat Childhood Cancer Research Consortium, a network of over 50 universities and children's hospitals based at Penn State College of Medicine, to develop innovative solutions for healthcare and human condition improvement using molecular science and AI.
Moreover, in December 2023, U.S. Food and Drug Administration (FDA) approved the first drug based on Sholler’s research and clinical trials she led through the Beat Childhood Cancer Research Consortium ? to reduce the risk of relapse for pediatric high-risk neuroblastoma patients.
Covid 19 Impact Analysis
COVID-19 had a significant effect on the world’s pediatric oncology healthcare workforce, with deleterious effects felt across. COVID-19 and pediatric oncology providers of all country income groups, reflecting the truly global nature of the pandemic’s impact. To prevent potentially devastating impacts, it is imperative that healthcare organizations around the world implement measures that support providers, both as the current pandemic evolves and in planning for future catastrophic events.
Market Segmentation
By Drug Type
- Eflornithine [Iwilfin]
- Entrectinib [Rozlytrek]
- Nivolumab [Opdivo]
- Bosutinib [Bosulif]
- Dabrafenib [Tafinlar]
- Others
By Indication
- Leukemia
- Lymphoma
- Brain Tumors
- Neuroblastoma
- Wilms Tumor
- Others
By Route of Administration
- Oral
- Topical
- Intravenous
- Others
By End User
- Hospitals
- Specialty Clinics
- Cancer Research Institutes
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include US WorldMeds, Novartis, Bristol Myers Squibb, Pfizer Inc., ORPHELIA Pharma, Day One Pharmaceuticals, Celon Labs, United Therapeutics, Y-mAbs Therapeutics, Inc., Servier Pharmaceuticals LLC among others.
Key Developments
- In March 2024, Pune-based Gennova Biopharmaceuticals announced the launch of India’s first paediatric pack size of pegaspargase, HAMSYL ? Junior, which will now be available in a 1500 IU pack size. This marks a significant milestone in advancing healthcare for Indian children suffering from an orphan disease called Acute Lymphoblastic Leukaemia (ALL), a rare and challenging form of blood cancer primarily affecting children.
- In September 2023, Cincinnati Children’s, the top-ranked pediatric hospital and top-ranked cancer program in the country by U.S. News & World Report, launched its first-of-its-kind Advanced Leukemia Therapies and Research Center. The centre will integrate the expertise of the world-class research and clinical programs at Cincinnati Children’s and increase patient access to cutting-edge clinical trials.
Why Purchase the Report?
- To visualize the global pediatric oncology drugs market segmentation based on drug type, indication, route of administration, end user and region as well as understand key commercial assets and players.
- identify commercial opportunities by analyzing trends and co-development.
- excel data sheet with numerous data points of the pediatric oncology drugs market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global pediatric oncology drugs market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise of innovations in pediatric oncology
4.1.1.2. Rise in the prevalence of childhood cancers
4.1.2. Restraints
4.1.2.1. Lack of professionals
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Eflornithine [Iwilfin] *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Entrectinib [Rozlytrek]
7.4. Nivolumab [Opdivo]
7.5. Bosutinib [Bosulif]
7.6. Dabrafenib [Tafinlar]
7.7. Others
8. By Indication
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Leukemia *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Lymphoma
8.4. Brain Tumors
8.5. Neuroblastoma
8.6. Wilms Tumor
8.7. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Topical
9.4. Intravenous
9.5. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Cancer Research Institutes
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. South Korea
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. US WorldMeds *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Novartis
13.3. Bristol Myers Squibb
13.4. Pfizer Inc
13.5. ORPHELIA Pharma
13.6. Day One Pharmaceuticals
13.7. Celon Labs
13.8. United Therapeutics
13.9. Y-mAbs Therapeutics, Inc
13.10. Servier Pharmaceuticals LLC

LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us